HomeAI · summaries
Storia in 4 fonti
Four questions on new safety warnings for Neurocrine’s Vykat XR
The treatment has been linked to seven deaths, largely due to heart or respiratory problems. It has also been associated with over 100 serious adverse events in Prader-Willi patients, raising safety and sales concerns.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Experts Flag Potential Safety Concerns in New Prader-Willi Drug
7 deaths and over 100 serious adverse events reported to FDA after treatment with Vykat XR
- ·
benzinga.com
What's Going On With Neurocrine Biosciences Stock On Wednesday? - Neurocrine Biosciences (NASDAQ:NBIX)
Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.
